title: microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
abstract: microRNA-217 (miR-217) is frequently dysregulated in cancer. Here, we report that miR-217 levels were lower in tumor tissue compared with the adjacent normal tissue. Low levels of miR-217 were associated with aggressive tumor phenotypes and poor overall survival in gastric cancer patients. The ectopic expression of miR-217 inhibited cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo, whereas knockdown of endogenous miR-217 increased cell proliferation and invasion. Further experiments revealed that Polycomb group protein enhancer of zeste homolog 2 (EZH2) was a direct target of miR-217 in gastric cancer cells. Knockdown of EZH2 mimicked the tumor-suppressive effects of miR-217 in gastric cancer cells, whereas the reintroduction of EZH2 abolished its effects. Taken together, these results demonstrated that miR-217 may be used as a prognostic marker, and the newly identified miR-217-EZH2 axis may be a potential target in the development of therapeutic strategies for gastric cancer patients.
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Dong-liang
authors: DL
authors: Chen
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Dong-sheng
authors: DS
authors: Zhang
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Yun-xin
authors: YX
authors: Lu
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Le-zong
authors: LZ
authors: Chen
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Zhao-lei
authors: ZL
authors: Zeng
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Ming-ming
authors: MM
authors: He
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Feng-hua
authors: FH
authors: Wang
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Yu-hong
authors: YH
authors: Li
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Hui-zhong
authors: HZ
authors: Zhang
authors: Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Helene
authors: H
authors: Pelicano
authors: Department of Pathology, Unit 85, Center for RNAi and Non-Coding RNA, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Wei
authors: W
authors: Zhang
authors: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
authors: Rui-hua
authors: RH
authors: Xu
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D015536:Down-Regulation; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D063151:Polycomb Repressive Complex 2 / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D034622:RNA Interference; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D014162:Transfection
chemical_list: C553315:MIRN217 microRNA, human; D035683:MicroRNAs; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2
keywords: EZH2; gastric cancer; metastasis; microRNA; microRNA-217